IL32 and hepatocellular carcinoma: Interestingly, serum IL-32 is gradually increased from the cohorts of the control, acute hepatitis, chronic hepatitis, liver cirrhosis, and HCC (27), further linking IL-32 and its pro-inflammatory effects with the severity and duration of hepatic damage.